• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 14, 2017

View Archived Issues

Lawmakers running out of patience on prescription drug prices

"Get your act together or else ..." was the message Republican and Democrat alike delivered Wednesday to drug companies, insurers and pharmacy benefit managers (PBMs) during a House subcommittee hearing on the prescription drug supply chain and its impact on drug prices. Read More

Braking good: Myeloid bid draws $62M series B round for Pionyr, headed to clinic

With $62 million in series B cash, Pionyr Immunotherapeutics Inc. hopes to "get initial human readouts in a couple of programs – at least one, maybe a second," CEO Steven James told BioWorld. The San Francisco-based company is advancing its Myeloid Tuning technology, which rebalances the tumor microenvironment, an effort that could work especially well with checkpoint inhibitors. Read More

GW Pharma sees Sativex as add-on to Epidiolex as it regains U.S. rights from Otsuka

DUBLIN – Two years after a failed effort to develop the cannabinoid product Sativex (nabiximols) as a therapy for cancer pain in the U.S., GW Pharmaceuticals plc and Otsuka Pharmaceutical Co. Ltd. are finally terminating an alliance that dates back more than a decade. Read More

Allakos rakes in $100M series B, stays mum (still) on development plans

Allakos Inc., which has deflected questions about its technology since its 2012 founding, continued to let its fundraising prowess do the talking after completing a $100 million series B to advance AK-002, a therapeutic antibody the company called its lead program, in disease areas ranging from gastrointestinal (GI) to dermatologic and ocular diseases. Read More

Financings

Fennec Pharmaceuticals Inc., of Research Triangle Park, N.C., completed its previously disclosed underwritten public offering of about 2.3 million common shares at $8.50 each. The firm also issued an additional 135,670 common shares in connection with the partial exercise of the underwriters' overallotment option. The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) was about $21.1 million. Wedbush Pacgrow acted as the sole book-running manager for the offering. H.C. Wainwright & Co. served as the co-manager. Read More

Other news to note

Xcell Biologix, of Kennesaw, Georgia, said it entered an exclusive worldwide license agreement with the Wake Forest Institute for Regenerative Medicine, part of Wake Forest School of Medicine, for development and commercialization of its amnion-derived product candidates that accelerate wound closure and reepithelialization for the protection, healing and repair of chronic wounds and severe burns. Terms were not disclosed. Read More

In the clinic

Mabvax Therapeutics Holdings Inc., of San Diego, completed enrollment and dosing in the initial cohort of a phase I trial testing its antibody-based radioimmunotherapy, MVT-1075, for the treatment of pancreatic, colon and lung cancers. The trial is designed to determine the maximum tolerated dose and safety profile of MVT-1075, but the trial will also measure tumor response rate and duration of response by RECIST 1.1, and determine dosimetry and pharmacokinetics. Interim data are expected in the first quarter of 2018. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe